Form 4: Jazz Pharmaceuticals Executive Renee D Gala Reports Acquisition of Ordinary Shares

Renee D Gala, President & COO of Jazz Pharmaceuticals, reports the acquisition of 19,916 ordinary shares and a grant of restricted stock units.

Summary

• On March 1, 2024, Renee D Gala, President & COO of Jazz Pharmaceuticals, acquired 19,916 ordinary shares.
• The shares were acquired at a price of $0.0.
• Following the transaction, Gala directly owns 60,715 ordinary shares.
• Gala also received restricted stock units under the company's 2011 Equity Incentive Plan.
• These restricted stock units vest in equal annual installments over four years, starting March 5, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock transactions by an executive. The acquisition of shares and grant of restricted stock units are generally seen as a positive sign, but it's not a major event.

Positives

• The acquisition of shares by a high-ranking executive could be interpreted as a positive signal about the company's prospects.

Future Outlook

The restricted stock units vest in equal annual installments over four years, measured from the vesting commencement date of March 5, 2024.

Industry Context

Executive stock ownership is a common practice in publicly traded companies to align management's interests with those of shareholders. Form 4 filings are a standard part of regulatory compliance.

Comparison to Industry Standards

• Executive compensation packages, including stock options and restricted stock units, are common in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize equity-based compensation to incentivize their executives.
• The vesting schedule of four years is a typical timeframe for such grants.

Key Dates